First-line pembrolizumab monotherapy was approved for stages IIB–IV NSCLC with ≥50% of PD-L1 expression and without EGFR mutation, or ALK or ROS1 rearrangement based on data from two clinical trials, KEYNOTE-010 and KEYNOTE-024, conducted in NSCLC patients with positive PD-L1 expression [14,19]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.